Improving access and affordability could be transformative for public health, given that about 88% of Americans are ...

The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...

GOP leaders are racing to try to get the bill to the White House by July 4. The multi-trillion-dollar bill would unlock tax ...

"It's criminal to put someone on a GLP-1 and not put them on a dietary plan," says Phil Vella, founder of Vita Bella Health, ...

Josephs joins forces with LifeRx.md to redefine health through doctor-led GLP‑1 wellness programs—merging celeb credibility ...

Dr. Mahsa Tehrani discusses how patients use medication to help them lose weight on 'America Reports.' ...

According to the CDC, 1 in 5 American adults is living with obesity. In recent years, many have turned to weight loss drugs ...

Instant ramen maker Nissin Foods is leveraging the buzz around GLP-1s to launch in the US a trio of decadent tasting frozen ...

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.